The biotech industry is undergoing a seismic shift, driven by artificial intelligence (AI) that accelerates drug discovery, optimizes protein engineering and personalizes medicine. As AI continues to reshape biotech, several innovative start-ups are emerging as leaders in this space. Below, we’ve highlighted five AI-powered biotech companies making waves, based on their technological breakthroughs, funding milestones and industry impact.
1. Insilico Medicine
Location: Cambridge, USA
Focus: AI-driven drug discovery and aging research
Key AI Platform: Pharma.AI (integrates target discovery, molecule generation and clinical trial prediction)
Why Watch?
- First AI-Designed Drug in Clinical Trials: Insilico’s idiopathic pulmonary fibrosis drug, INS018_055, became the first fully AI-discovered and designed molecule to enter Phase 2 trials in 2023, marking a major industry milestone.
- Notable Funding: Raised USD 110m in Series E in March this
2. Cradle Bio
Location: Delft, Netherlands
Focus: AI-powered protein engineering
Key AI Platform: Generative AI for protein design
Why Watch?
- Major Partnerships: Collaborations include Novo Nordisk and Ginkgo Bioworks to optimize proteins for therapeutic and industrial applications.
- Notable Funding: Raised USD 74m in November 2024, bringing total funding to over USD 100m.
- Applications: Designs enzymes, vaccines and antibodies with improved stability, binding affinity and expression.
3. Iktos
Location: Paris, France
Focus: AI-driven small molecule discovery
Key AI Platform: Makya (generative AI for molecule design) and Spaya (retrosynthesis AI)
Why Watch?
- Strategic Collaborations: Worked with Janssen, Merck and Pfizer, incorporating its AI platform in over 50 partnerships.
- Funding Milestones: Secured EUR 15.50m (USD 16.4m) in Series A funding in March 2023 and a EUR 2.5m EIC Accelerator grant in February 2025.
- Pipeline Focus: Developing preclinical candidates for inflammatory diseases, oncology and obesity.
4. CHARM Therapeutics
Location: London, UK
Focus: Small molecule medicines using 3D deep learning
Key AI Platform: DragonFold (predicts 3D protein-ligand structures at an atomic level to design highly specific drugs)
Why Watch?
- Strong Financial Backing: Raised over USD 70m to date.
- Advancing Oncology Pipeline: The company is leveraging its DragonFold platform to advance its own pipeline of precision oncology drugs, with a lead program targeting a key oncogene.
5. Enveda Biosciences
Location: Boulder, USA
Focus: Using AI to identify and optimize novel drug candidates derived from natural products
Key AI Platform: A platform that integrates mass spectrometry with machine learning to analyze complex natural compound libraries and predict bioactive molecules.
Why Watch?
- Novel Discovery Approach: Enveda’s platform aims to systematically characterize medicinal compounds from botanical sources, attempting to address challenges in natural product drug discovery.
- Pipeline Status: The company is currently advancing multiple preclinical candidates for inflammatory and neurological conditions.
- Recent Financing: Sanofi invested USD 20m in Series C funding in February this year.